Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
Supplementary Table 15)
It is contraindicated for use in patients with a personal or family history of medullary thyroid carcinoma and in those with multiple endocrine neoplasia type 2
Your doctor will start you on a low dose and slowly raise it if your body tolerates the medication
(2024, September) Retatrutide is a novel triple-agonist targeting GLP-1, GIP, and glucagon receptors, showing in phase 2 trials that it can deliver remarkably large weight losses (up to ~24% over 48 weeks in people with obesity) along with strong improvements in HbA1c, lipid profiles, liver fat (in NAFLD), insulin sensitivity, and other cardiometabolic markers
Eli Lilly is expected to present this data to the U.S
What do the experts say
US$ 22.01
US$ 24.61
US$ 22.32
US$ 24.72
US$ 25.93
US$ 21.56
